Welcome to our dedicated page for Scotts Miracle Gr SEC filings (Ticker: SMG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scotts Miracle-Gro Company (NYSE: SMG) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, governance and financial condition. As an Ohio‑incorporated issuer with common shares listed on the New York Stock Exchange, ScottsMiracle-Gro uses periodic reports and current reports to describe its branded consumer lawn and garden business, indoor and hydroponic growing operations and related financing arrangements.
On this page, you can review core filings such as the annual report on Form 10‑K and quarterly reports on Form 10‑Q, which include segment information for U.S. Consumer, Hawthorne and Other, along with discussions of risk factors, liquidity, capital resources and segment performance. These filings also elaborate on topics referenced in company news releases, such as gross margin trends, leverage, free cash flow and the role of credit facilities and receivables programs in the capital structure.
Current reports on Form 8‑K provide more targeted updates. Recent 8‑K filings describe a Seventh Amended and Restated Credit Agreement establishing senior secured loan facilities, amendments to a master receivables purchase agreement, results of operations for specific quarters and changes to the board of directors and equity award documentation. These filings outline key terms such as leverage and interest coverage covenants, security packages and the use of proceeds for working capital and general corporate purposes.
Definitive proxy statements on Schedule 14A offer detail on corporate governance and executive compensation. ScottsMiracle-Gro’s proxy materials cover board composition, committee responsibilities, director independence, say‑on‑pay proposals, long‑term incentive plan terms, stock ownership guidelines and severance and change‑in‑control arrangements.
This filings page combines real‑time access to new EDGAR submissions with AI‑generated summaries that explain the structure and implications of each document. Users can quickly identify items such as 10‑K and 10‑Q reports, 8‑K current reports, proxy statements and exhibits related to credit agreements or incentive plans, and use the summaries to focus on the sections most relevant to their analysis of SMG.
Scotts Miracle-Gro director Brian E. Sandoval reported the conversion of equity awards into common shares. On February 3, 2026, 336 dividend equivalent rights were exercised at $0 and delivered as 336 common shares.
Following this transaction, Sandoval directly held 18,723 common shares of Scotts Miracle-Gro and 636 dividend equivalent rights. The filing notes that restricted stock units convert into common shares on a one-for-one basis and references a prior grant of 2,553 restricted stock units with accruing dividend equivalent rights.
Scotts Miracle-Gro director Peter E. Shumlin reported an automatic conversion of 336 dividend equivalent rights into 336 common shares on February 3, 2026, at an exercise price of $0.
Following this transaction, he directly held 30,846 common shares and 692 dividend equivalent rights.
The Scotts Miracle-Gro Company reported a larger net loss as it moves to exit its Hawthorne business. For the quarter ended December 27, 2025, net sales from continuing operations were $354.4 million, down 3.3% from $366.6 million a year earlier, mainly from lower U.S. fertilizer, grass seed and controls volume partly offset by stronger soils sales and pricing.
Gross margin improved to 25.0% from 24.1% as higher pricing and lower manufacturing costs more than offset weaker volume. Loss from continuing operations narrowed to $47.8 million from $66.1 million due to better margins, lower restructuring charges, reduced SG&A and lower interest expense.
The company classified its Hawthorne business as held for sale and recorded a non‑cash pre‑tax charge of $104.8 million, driving discontinued operations loss of $77.2 million and total net loss of $125.0 million. Operating cash outflow improved to $370.4 million from $445.3 million, while total debt was $2,542.3 million and equity reflected a deficit of $500.6 million. The leverage ratio under its credit agreement was 4.03, below the 5.00 maximum covenant.
Scotts Miracle-Gro director Roberto Candelino reported acquiring additional company stock. On 01/30/2026, he acquired 3,271 Common Shares at a reported price of $0 per share, likely reflecting a no-cash equity award. After this transaction, he beneficially owned 6,614 Common Shares, held directly.
Scotts Miracle-Gro director Edith Aviles acquired 3,271 common shares on January 30, 2026 at a reported price of $0 per share. After this transaction, she directly beneficially owns 13,968 common shares of the company.
Scotts Miracle-Gro executive Christopher Hagedorn reported new equity awards and a minor share transaction. He received a stock option grant for 29,649 common shares at an exercise price of $64.22 per share, with the option expiring on 01/30/2036. The option covers 29,649 underlying common shares and is held directly.
He also reported an acquisition coded "J" of 4.179 common shares at a price of $51.93 per share. Following this transaction, he directly beneficially owned 60,115.4664 common shares of Scotts Miracle-Gro.
Scotts Miracle-Gro director Katherine Hagedorn Littlefield reported receiving 3,271 Common Shares of the company on January 30, 2026. The shares were acquired at a reported price of $0 per share, indicating a grant or similar no-cost award.
After this transaction, she directly holds 10,211 Common Shares. She is also reported as having an indirect interest in 2,774,291 Common Shares held by Hagedorn Partnership, L.P., reflecting her proportionate interest and that of certain family members in the partnership’s holdings.
The Scotts Miracle-Gro Company director reports new share award. Director David C. Evans acquired 3,271 common shares of Scotts Miracle-Gro on January 30, 2026 in a transaction reported at $0 per share, indicating a grant or award rather than an open-market purchase. After this transaction, he beneficially owns 27,724 common shares, held directly.
Scotts Miracle-Gro director Austin Scott Miller acquired additional company shares. On 01/30/2026, he acquired 3,271 common shares at a price of $0 per share, increasing his direct holdings to 4,686 common shares.
Scotts Miracle-Gro director Nick Miaritis reported receiving 3,271 common shares on January 30, 2026, at a stated price of $0 per share. After this acquisition, he beneficially owned 6,231 common shares, held directly. The transaction was reported on a Form 4 insider trading report.